BPC-157 / TB-500

Volume Pricing

Price per pack (10 vials). Discount applies to this compound only – no mix and match.

BPC-157 / TB-500 Blend — Dual-Peptide Regenerative Research Stack

The BPC-157 / TB-500 blend combines two of the most extensively studied peptides in regenerative biology into a single research compound. BPC-157 — a 15-amino acid gastric pentadecapeptide — and TB-500 — a synthetic analog of the naturally occurring 43-amino acid peptide Thymosin Beta-4 — operate through mechanistically distinct but deeply complementary pathways. Where BPC-157 focuses on vascular remodeling, nitric oxide signaling, and multi-pathway tissue protection, TB-500 works primarily through cytoskeletal actin regulation and cell migration architecture. Together, they address both the vascular supply and the cellular construction side of tissue repair in a single protocol — making this blend the most commonly studied combination in musculoskeletal and systemic regenerative research.

Why the Combination Matters

Neither peptide alone covers the full regenerative picture. BPC-157 excels at initiating and sustaining the vascular environment for repair — driving angiogenesis, modulating inflammation, and protecting endothelial integrity. TB-500 operates at the cellular structural level — governing how cells move, adhere, and organize into repaired tissue. Researchers describe the pairing as complementary by design: BPC-157 builds the supply lines while TB-500 directs the construction.

Both peptides independently drive angiogenesis — BPC-157 via VEGFR2 and the Akt-eNOS axis, TB-500 through direct endothelial cell migration and VEGF pathway upregulation. This convergence on shared vascular endpoints is considered a key reason the combination produces research outcomes beyond what either compound achieves in isolation.

Research Applications

The BPC-157 / TB-500 blend is used in studies examining:

• Accelerated musculoskeletal repair — tendon, ligament, and muscle injury models where both vascular and cytoskeletal mechanisms are active simultaneously
• Wound healing endpoints including re-epithelialization rates, collagen deposition quality, and angiogenic density
• Comparative efficacy of the blend vs. each individual peptide across matched injury models
• Fibrosis reduction and scar formation prevention in soft tissue recovery
• Cardiac tissue repair and progenitor cell activation following ischemic injury models
• Neurological recovery in spinal cord compression and stroke models
• Gastrointestinal mucosal protection in combination with systemic regenerative signaling
• Gut-brain axis interactions when both peptides’ CNS-adjacent pathways are co-active

Specifications

Reconstitution

The blend arrives as co-lyophilized powder and is reconstituted as a single solution with bacteriostatic water prior to use. Use the formula:

Total mg (per peptide) ÷ Volume added (mL) = Concentration per peptide (mg/mL)

Example: 5mg/5mg vial + 2mL BAC water = 2.5mg/mL BPC-157 + 2.5mg/mL TB-500

Reconstituted peptide should be stored at 2–8°C and used within 28–30 days.

Protocol Notes

Both peptides in this blend have relatively short half-lives following parenteral administration, which shapes typical dosing frequency. TB-500’s cytoskeletal effects tend to be studied on less frequent schedules than BPC-157’s vascular and GI endpoints, making the blend’s protocol design an active area of research in itself.

Typical research dosing framework:

• BPC-157 dose: 200–500mcg per administration
• TB-500 dose: 300–600mcg per administration (some protocols use front-loaded or weekly schedules)
• Frequency: Once or twice daily (BPC-157 component); weekly or twice-weekly loading phases have been studied for TB-500 component
• Routes studied: Subcutaneous, intramuscular; localized administration near target tissue common in musculoskeletal models
• Study duration: 4–8 weeks for soft tissue endpoints; 8–12 weeks for cardiac and neurological endpoints

Commonly observed effects in research models:

• Local: Injection site irritation; generally well tolerated across both peptides in preclinical models
• Systemic: Both peptides individually show favorable preclinical safety profiles — no minimum toxic dose identified for BPC-157; TB-500 well tolerated across a range of animal models
• Other: Mild transient GI effects at higher doses in limited human-adjacent data; no genotoxic, teratogenic, or anaphylactic effects reported in preclinical studies for either compound

Research Stacks

BPC-157 / TB-500 is commonly paired in research settings with:

• GHK-Cu — GHK-Cu’s copper-dependent stimulation of collagen and elastin synthesis complements the angiogenic and actin-regulatory effects of the BPC-157/TB-500 blend; together they are studied for multi-pathway coverage in connective tissue and wound research.
• KPV — KPV provides targeted anti-inflammatory signaling at the mucosal level; it is paired with this blend in intestinal and systemic inflammatory models to assess combined modulation of cytokine and tissue repair pathways.
• Ipamorelin — Ipamorelin stimulates GH secretion without significant cortisol or prolactin elevation; it is combined with BPC-157/TB-500 in studies examining systemic recovery signals alongside local tissue repair mechanisms.

Purity Guarantee

Every batch is ≥99% purity per peptide. If you independently test your compound and the results don’t match — send us the COA and we’ll issue store credit, no questions asked.